MSFT   212.64 (+0.92%)
FB   245.33 (+2.10%)
GOOGL   1,513.59 (+0.93%)
AMZN   3,045.78 (-0.37%)
NVDA   399.54 (+1.52%)
CGC   16.58 (-2.13%)
BABA   237.59 (-1.00%)
MU   49.99 (-1.83%)
TSLA   1,396.20 (+1.80%)
AMD   53.45 (+0.09%)
GILD   76.53 (-0.30%)
NFLX   495.10 (+0.26%)
MSFT   212.64 (+0.92%)
FB   245.33 (+2.10%)
GOOGL   1,513.59 (+0.93%)
AMZN   3,045.78 (-0.37%)
NVDA   399.54 (+1.52%)
CGC   16.58 (-2.13%)
BABA   237.59 (-1.00%)
MU   49.99 (-1.83%)
TSLA   1,396.20 (+1.80%)
AMD   53.45 (+0.09%)
GILD   76.53 (-0.30%)
NFLX   495.10 (+0.26%)
MSFT   212.64 (+0.92%)
FB   245.33 (+2.10%)
GOOGL   1,513.59 (+0.93%)
AMZN   3,045.78 (-0.37%)
NVDA   399.54 (+1.52%)
CGC   16.58 (-2.13%)
BABA   237.59 (-1.00%)
MU   49.99 (-1.83%)
TSLA   1,396.20 (+1.80%)
AMD   53.45 (+0.09%)
GILD   76.53 (-0.30%)
NFLX   495.10 (+0.26%)
MSFT   212.64 (+0.92%)
FB   245.33 (+2.10%)
GOOGL   1,513.59 (+0.93%)
AMZN   3,045.78 (-0.37%)
NVDA   399.54 (+1.52%)
CGC   16.58 (-2.13%)
BABA   237.59 (-1.00%)
MU   49.99 (-1.83%)
TSLA   1,396.20 (+1.80%)
AMD   53.45 (+0.09%)
GILD   76.53 (-0.30%)
NFLX   495.10 (+0.26%)
Log in

NASDAQ:ENDPEndo International Stock Price, Forecast & News

$3.74
+0.12 (+3.31 %)
(As of 07/7/2020 12:43 PM ET)
Add
Compare
Today's Range
$3.67
Now: $3.74
$4.44
50-Day Range
$3.43
MA: $3.74
$4.51
52-Week Range
$1.97
Now: $3.74
$7.10
Volume793,946 shs
Average Volume5.72 million shs
Market Capitalization$859.12 million
P/E RatioN/A
Dividend YieldN/A
Beta1.54
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals. The U.S. Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, abuse-deterrent products, liquids, semi-solids, patches, powders, ophthalmics, sprays, and sterile injectables, as well as products for the pain management, urology, central nervous system disorders, immunosuppression, oncology, women's health, and cardiovascular disease markets. The U.S. Branded Pharmaceuticals segment provides XIAFLEX for the treatment of Dupuytren's contracture and Peyronie's diseases; SUPPRELIN LA for central precocious puberty treatment; TESTOPEL, a long-acting implantable pellet for the treatment of central precocious puberty; NASCOBAL, a nasal spray to treat vitamin B12 deficiency; and AVEED for the treatment of hypogonadism. This segment also offers pain management products, such as PERCOCET, VOLTAREN Gel, and LIDODERM; TESTIM Gel for the treatment of endogenous testosterone; and FORTESTA Gel for hypogonadism treatment. The International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, and oncology. It sells its branded pharmaceuticals and generics directly to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors, as well as through wholesale drug distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland.
Read More
Endo International logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.2Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.48 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:ENDP
CUSIP29264F20
Phone011-353-1268-2000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.91 billion
Cash Flow$5.58 per share
Book Value($3.82) per share

Profitability

Net Income$-422,640,000.00

Miscellaneous

Employees3,172
Market Cap$859.12 million
Next Earnings Date8/6/2020 (Confirmed)
OptionableOptionable

Receive ENDP News and Ratings via Email

Sign-up to receive the latest news and ratings for ENDP and its competitors with MarketBeat's FREE daily newsletter.

Endo International (NASDAQ:ENDP) Frequently Asked Questions

How has Endo International's stock been impacted by COVID-19 (Coronavirus)?

Endo International's stock was trading at $3.89 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ENDP stock has decreased by 3.9% and is now trading at $3.74. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Endo International?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Endo International in the last year. There are currently 1 sell rating, 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Endo International.

When is Endo International's next earnings date?

Endo International is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Endo International.

How were Endo International's earnings last quarter?

Endo International PLC (NASDAQ:ENDP) released its quarterly earnings data on Thursday, May, 7th. The company reported $0.95 earnings per share for the quarter, beating the consensus estimate of $0.55 by $0.40. The firm earned $820.40 million during the quarter, compared to analysts' expectations of $713.62 million. Endo International had a negative net margin of 9.09% and a negative return on equity of 91.00%. The business's revenue for the quarter was up 13.9% compared to the same quarter last year. During the same quarter last year, the firm earned $0.60 earnings per share. View Endo International's earnings history.

What price target have analysts set for ENDP?

6 brokerages have issued twelve-month price objectives for Endo International's stock. Their forecasts range from $3.00 to $7.00. On average, they expect Endo International's share price to reach $5.83 in the next year. This suggests a possible upside of 56.0% from the stock's current price. View analysts' price targets for Endo International.

Has Endo International been receiving favorable news coverage?

News stories about ENDP stock have trended negative this week, according to InfoTrie. InfoTrie scores the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Endo International earned a news sentiment score of -2.1 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news about Endo International.

Who are some of Endo International's key competitors?

What other stocks do shareholders of Endo International own?

Who are Endo International's key executives?

Endo International's management team includes the following people:
  • Mr. Paul V. Campanelli, Pres, CEO & Director (Age 57)
  • Mr. Blaise Coleman, Exec. VP & CFO (Age 45)
  • Mr. Terrance J. Coughlin, Exec. VP & COO (Age 53)
  • Mr. Matthew Joseph Maletta, Exec. VP & Chief Legal Officer (Age 47)
  • Mr. Antonio R. Pera, Pres of Par Pharmaceutical (Age 62)

What is Endo International's stock symbol?

Endo International trades on the NASDAQ under the ticker symbol "ENDP."

How do I buy shares of Endo International?

Shares of ENDP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Endo International's stock price today?

One share of ENDP stock can currently be purchased for approximately $3.74.

How big of a company is Endo International?

Endo International has a market capitalization of $859.12 million and generates $2.91 billion in revenue each year. The company earns $-422,640,000.00 in net income (profit) each year or $2.38 on an earnings per share basis. Endo International employs 3,172 workers across the globe.

What is Endo International's official website?

The official website for Endo International is www.endo.com.

How can I contact Endo International?

Endo International's mailing address is First Floor Minerva House Simmonscourt Road Ballsbridge, Dublin L2, 19355. The company can be reached via phone at 011-353-1268-2000 or via email at [email protected]

This page was last updated on 7/7/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.